[A renoprotective effect of enalapril in chronic transplantation nephropathy].
OBJECTIVE
To study safety and efficacy of ACE inhibitor enalapril in chronic transplantation nephropathy (CTN) as well as nephroprotective efficacy of this drug in various clinical variants of CTN.


METHODS
A retrospective study covered 220 recipients with CRF. The patients were divided into the study group (n = 103) and the control group (n = 117). The study group was given ACE inhibitor enalapril the efficacy of which was assessed by arterial pressure (systolic, diastolic, mean) dynamics, 24 h proteinuria and the rate of CTN progression. This rate was suggested by probability of plasm creatinin doubling (Kaplan-Meier technique).


RESULTS
Enalapril significantly inhibited CTN progression running with minimal or marked proteinuria, had a pronounced hypotensive effect, promoted stabilization of minimal proteinuria (in CTN with minimal proteinuria) or reduction of protein excretion (in a proteinuric variant of CTN).


CONCLUSIONS
Use of enalapril in CTN in a daily dose 10 mg maximum is safe and can be used for inhibition of CTN progression.
Tomilina
N A
NA
Bagdasarian
A R
AR
Stoliarevich
E S
ES
Sukhanov
A V
AV
Fedorova
N D
ND
Il'inskiĭ
I M
IM
Tyrin
V V
VV
Frolov
A V
AV
D000293:Adolescent; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D004656:Enalapril / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D000959:Antihypertensive Agents; D004656:Enalapril